RADIOTHERAPY GRANT

Article

AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

Related Videos
Related Content

Oxidative Damage Induces Increase of Pro-Inflammatory IL-15 in Vitiligo

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Addressing Disparities in Atopic Dermatitis Education on TikTok

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

Oxidative Damage Induces Increase of Pro-Inflammatory IL-15 in Vitiligo

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Addressing Disparities in Atopic Dermatitis Education on TikTok

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023

Oxidative Damage Induces Increase of Pro-Inflammatory IL-15 in Vitiligo

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Addressing Disparities in Atopic Dermatitis Education on TikTok

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

SARS-CoV-2 Associated With Increased Incidence of Psoriasis

October 3rd 2023
© 2023 MJH Life Sciences

All rights reserved.